OPA1 and hepatocellular carcinoma: Taking LIHC as an example, some researchers found that OPA1 downregulation can enhance the sensitivity of hepatocellular carcinoma to chemotherapy drug sorafenib, which indicates that low expression of OPA1 is associated with a better prognosis of hepatocellular carcinoma.